Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Costanza Leonardi"'
Autor:
Simone Potenti, Lorenzo Spada, Marco Fusè, Giordano Mancini, Andrea Gualandi, Costanza Leonardi, Pier Giorgio Cozzi, Cristina Puzzarini, Vincenzo Barone
Publikováno v:
ACS Omega, Vol 6, Iss 20, Pp 13170-13181 (2021)
Externí odkaz:
https://doaj.org/article/5aa5e5922399433c9869162016c4b02a
Autor:
Daniele Ragno, Olga Bortolini, Sofia Toldo, Costanza Leonardi, Carmela De Risi, Alessandro Massi, Graziano Di Carmine
Publikováno v:
European Journal of Organic Chemistry. 2022
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94f2ad08bac26a0e08c51642ebdfcc8b
https://doi.org/10.1002/ejoc.202200482
https://doi.org/10.1002/ejoc.202200482
Autor:
Lynette M. Sholl, Geoffrey R. Oxnard, Giuseppe Lamberti, Ying-Chun Lo, Stephen R. Fairclough, Liam F. Spurr, Adem Albayrak, Deepti Venkatraman, Tom C. Nguyen, Renato Umeton, Yvonne Y. Li, Magda Bahcall, Pasi A. Jänne, Marina S.D. Milan, Mark M. Awad, Andrew D. Cherniack, Cloud P. Paweletz, Biagio Ricciuti, Gonzalo Recondo, Jianwei Che, Giulia Costanza Leonardi, Kristin S Price, Mizuki Nishino
Publikováno v:
Clinical Cancer Research. 26:2615-2625
Purpose:Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of resistance to type I and type II MET TKIs and their impact on sequential MET TKI the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f77a1442ed95a93dfcaa6ab0190cd23
https://doi.org/10.1158/1078-0432.ccr-19-3608
https://doi.org/10.1158/1078-0432.ccr-19-3608
Autor:
Carmela De Risi, Arianna Brandolese, Daniele Ragno, Olga Bortolini, Graziano Di Carmine, Alessandro Massi, Costanza Leonardi
Publikováno v:
European Journal of Organic Chemistry. 2020:2439-2447
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f5baf5e6561ee01db56601c74697987
https://doi.org/10.1002/ejoc.202000151
https://doi.org/10.1002/ejoc.202000151
Autor:
Jessica Hossa, Giulia Costanza Leonardi, Chiara Ambrogio, Taek-Chin Cheong, Ines Mota, Qi Wang, Cinzia Martinengo, Roberto Chiarle, Birgit Geoerger, Luca Mologni, Carlo Gambacorti-Passerini, Laurence Brugières, Elif Karaca-Atabay, Achille Pich, Nina Prokoph, Carmen Mecca, Suzanne D. Turner, Claudia Voena, Enrico Patrucco, Giulia Mura
Publikováno v:
Blood
Anaplastic large cell lymphomas (ALCLs) frequently carry oncogenic fusions involving the anaplastic lymphoma kinase (ALK) gene. Targeting ALK using tyrosine kinase inhibitors (TKIs) is a therapeutic option in cases relapsed after chemotherapy, but TK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ad5582f7b1969b4fe80d45b81002ac0
https://hdl.handle.net/2318/1833338
https://hdl.handle.net/2318/1833338
Autor:
Guy Ben-Betzalel, Wei Qiao, Justine V. Cohen, Sarah A. Weiss, Lisa Manuzzi, Ibraheim Hajir, Mark P. Lythgoe, Douglas B. Johnson, Sai Ching J. Yeung, David Faleck, Gal Markel, Michael Dougan, Dwight H. Owen, Jiajia Zhang, Giulia Costanza Leonardi, Mark M. Awad, Christina A. Arnold, Robin B. Mendelsohn, Hamzah Abu-Sbeih, MacLean C. Sellers, Giuseppe Lamberti, Nick Powell, Elad Sharon, Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, David J. Pinato, Yinghong Wang, Aanika Balaji
Publikováno v:
Journal of Clinical Oncology
Web of Science
Web of Science
PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who recei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff2684338f7749edd040faed2ca055aa
http://europepmc.org/articles/PMC7030892
http://europepmc.org/articles/PMC7030892
Publikováno v:
OncoTargets and Therapy. 12:3171-3179
The development of deep-sequencing methods is now unveiling a new landscape of previously undetected gene fusion across different tumor types. Chromosomal translocation involving the NTRK gene family occur across a wide range of cancers in both child
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7aa48b244d6d241f712291c774809f75
https://doi.org/10.2147/ott.s177051
https://doi.org/10.2147/ott.s177051
Autor:
Paolo Puccetti, Rita Chiari, Francesca Fallarino, Vanessa Bianconi, Biagio Ricciuti, Giulia Costanza Leonardi, Amirhossein Sahebkar, Matteo Pirro, Sara Baglivo
Publikováno v:
Pharmacology & Therapeutics. 196:105-116
Immunotherapy through immune checkpoint blockers (ICBs) is quickly transforming cancer treatment by improving patients' outcomes. However, innate and acquired resistance to ICBs remain a major challenge in clinical settings. Indoleamine 2,3-dioxygena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::667ac6b87968bcc8f439f3d559ce4583
https://doi.org/10.1016/j.pharmthera.2018.12.004
https://doi.org/10.1016/j.pharmthera.2018.12.004
Publikováno v:
International Journal of Oncology
Cancer affects millions of individuals worldwide. Thus, there is an increased need for the development of novel effective therapeutic approaches. Tumorigenesis is often coupled with immunosuppression which defeats the anticancer immune defense mechan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::054889d5bc4f5b6dc96ecd35e78e753e
https://hdl.handle.net/20.500.11769/524018
https://hdl.handle.net/20.500.11769/524018